The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessAbstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,701–1,800 of 3,967
Current and Future Idiopathic Pulmonary Fibrosis Therapy
Richeldi, L., Baldi, F., Pasciuto, G., Macagno, F., & Panico, L. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.006 · Cited by 18
Shen, L., Lei, S., Huang, L., Li, S., Yi, S., Breitzig, M., Huang, M., Mo, X., Sun, H., Zheng, Q. Y., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.03.001 · Cited by 15
Sleep and interstitial lung disease
Myall, K. J., West, A., & Kent, B. D. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000620 · Cited by 16
The efficacy of pirfenidone in a sheep model of pulmonary fibrosis
Dewage, S. N. V., Organ, L. A., Koumoundouros, E., Derseh, H. B., Perera, K. U. E., Samuel, C. S., Stent, A. W., & Snibson, K. J. (2019) · Experimental Lung Research · doi:10.1080/01902148.2019.1695019 · Cited by 14
“The clinical benefit of pirfenidone treatment in IPF patients was assessed predominantly through assessment of lung function changes via a reduction in the decline of FVC.21,30 Therefore, our model of pulmonary fibrosis is able to utilize clinically relevant endpoints when assessing the effectiveness of novel therapeu…”
BackgroundMethodEasthausen, I. J., Podolanczuk, A. J., Hoffman, E. A., Kawut, S. M., Oelsner, E. C., Kim, J. S., Raghu, G., Stukovsky, K. H., Redline, S. S., McClelland, R. L., et al. (2020) · Respirology · doi:10.1111/resp.13783 · Cited by 16
Self-citationShedding light on developmental drugs for idiopathic pulmonary fibrosis
Spagnolo, P., Bonella, F., Ryerson, C. J., Τzouvelekis, Α., & Maher, T. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1782885 · Cited by 17
A novel tree shrew model of pulmonary fibrosis
Che, P., Wang, M., Larson‐Casey, J. L., Hu, R.-H., Cheng, Y., Hamdaoui, M. E., Zhao, X., Grytz, R., Carter, A. B., & Ding, Q. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00476-3 · Cited by 18
Balestro, E., Castelli, G., Bernardinello, N., Cocconcelli, E., Biondini, D., Fracasso, F., Rea, F., Saetta, M. P., Baraldo, S., & Spagnolo, P. (2020) · Chronic Respiratory Disease · doi:10.1177/1479973120958428 · Cited by 15
“Antifibrotic treatment (i.e., pirfenidone and nintedanib) slow down functional decline and disease progression of patients with IPF.7,8 In our study, nearly half of patients (48”
BackgroundInfluentialPastré, J., Barnett, S. D., Ksovreli, I., Taylor, J., Brown, A. W., Shlobin, O. A., Ahmad, K., Khangoora, V. S., Aryal, S., King, C. S., et al. (2021) · Respiratory Research · doi:10.1186/s12931-020-01600-z · Cited by 19
Self-citationGoos, T., Sadeleer, L. D., Yserbyt, J., Verleden, G. M., Vermant, M., Verleden, S. E., & Wuyts, W. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061330 · Cited by 17
Komatsu, M., Yamamoto, H., Kitaguchi, Y., Kawakami, S., Matsushita, M., Uehara, T., Kinjo, T., Wada, Y., Ichiyama, T., Urushihata, K., et al. (2021) · Medicine · doi:10.1097/md.0000000000025322 · Cited by 16
Kim, W., Lee, S. M., Kim, J. I., Ahn, Y., Park, S., Choe, J., & Seo, J. B. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26682 · Cited by 18
Bimodal fibrosis in a novel mouse model of bleomycin-induced usual interstitial pneumonia
Miura, Y., Lam, M., Bourke, J. E., & Kanazawa, S. (2021) · Life Science Alliance · doi:10.26508/lsa.202101059 · Cited by 18
Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Rønnow, S. R., Karsdal, M. A., Leeming, D. J., Bendstrup, E. M., Sand, J. M. B., & Shaker, S. B. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01684-3 · Cited by 20
Mooney, J. J., Reddy, S. R., Chang, E. Y., Broder, M. S., Gokhale, S., & Corral, M. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.12.1724 · Cited by 19
García-Fernández, F., Marchena‐Gómez, J., Morán, V. C., Hermida, M. I. G., Sotgiu, E., & Pérez, G. V. (2011) · PubMed · Cited by 14
Pemafibrate Attenuates Pulmonary Fibrosis by Inhibiting Myofibroblast Differentiation
Liu, Y., Chen, S., Yu, L., Deng, Y., Li, D., Yu, X., Chen, D., Lu, Y., Liu, S., & Chen, R. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108728 · Cited by 20
Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm
Boshra, M. S., Warda, A. E. A., Sayed, M. A., Elkomy, M. H., Alotaibi, N. H., Mohsen, M., & Sarhan, R. M. (2022) · Healthcare · doi:10.3390/healthcare10122387 · Cited by 19
Lee, J. K., Chung, C., Kim, J., Cho, H. S., & Kim, H. C. (2023) · Scientific Reports · doi:10.1038/s41598-023-32843-7 · Cited by 19
The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis
Podolanczuk, A. J., Richeldi, L., & Martínez, F. J. (2023) · JAMA · doi:10.1001/jama.2022.23955 · Cited by 17
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
Courtwright, A., Goldberg, H. J., Henske, E. P., & El‐Chemaly, S. (2017) · European Respiratory Review · doi:10.1183/16000617.0004-2016 · Cited by 16
Pulmonary fibrosis, part II: state-of-the-art patient management
Meyer, K. C. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1312347 · Cited by 17
Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by γ-ray irradiation in mice
Li, X., Ma, D., Zha, X., Quan, D., Pan, D., Sun, M., Hu, B., & Zhao, B. (2017) · Oncotarget · doi:10.18632/oncotarget.18487 · Cited by 15
Dellaripa, P. F. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.09.015 · Cited by 16
Capparelli, I., Fernandez, M., Otero, M. S., Steimberg, J., Brassesco, M., Campobasso, A., Palacios, S., Caro, F. M., Alberti, M. L., Rabinovich, R., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.09.011 · Cited by 20
Zhang, Y., Xin, Q., Wu, Z. S., Wang, C., Wang, Y., Wu, Q., & Niu, R. L. (2018) · Medical Science Monitor · doi:10.12659/msm.908702 · Cited by 17
Elicker, B. M., Kallianos, K. G., Jones, K. D., & Henry, T. S. (2018) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2018.11.010 · Cited by 18
Transbronchial cryobiopsy in diffuse parenchymal lung disease. A new star in the horizon.
Poletti, V. E., & Benzaquen, S. (2014) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 16
Dinnon, K. H., Leist, S. R., Okuda, K., Dang, H., Fritch, E. J., Gully, K. L., la Cruz, G. D., Evangelista, M. D., Asakura, T., Gilmore, R. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.15.480515 · Cited by 16
Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit
Massoud, G., Parish, M. A., Hazimeh, D., Moukarzel, P., Singh, B., Vaught, K. C. C., Segars, J., & Islam, M. S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112423 · Cited by 17
Chakraborty, A., Wang, C., Hodgson‐Garms, M., Broughton, B. R. S., Frith, J. E., Kelly, K., & Samuel, C. S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117259 · Cited by 16
Pezet, M. G., Torres, J. A., Thimraj, T. A., Matković, I., Schrode, N., Murray, J. W., Saqi, A., Beaumont, K. G., & Snoeck, H. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02569-0 · Cited by 30
Hou, Z., Dong, B., Yao, Q., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00515-7 · Cited by 15
Investigational drugs for idiopathic pulmonary fibrosis
Varone, F., Montemurro, G., Macagno, F., Calvello, M., Conte, E. G., Intini, E., Iovene, B., Leone, P. M., Mari, P., & Richeldi, L. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1364361 · Cited by 15
Povitz, M., Li, L., Hosein, K., Shariff, S. Z., & Mura, M. (2019) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2019.03.012 · Cited by 15
Hwang, H., Lee, J., Choi, S. M., Lee, Y. J., Cho, Y., Yoon, H. I., Lee, J. H., Lee, C., Kim, Y. W., & Park, J. S. (2021) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.559 · Cited by 15
Spatially Resolved Identification of Transglutaminase Substrates by Proteomics in Pulmonary Fibrosis
Takeuchi, T., Tatsukawa, H., Shinoda, Y., Kuwata, K., Nishiga, M., Takahashi, H., Hase, N., & Hitomi, K. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0012oc · Cited by 18
BMP3b is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts
Suzuki, A., Sakamoto, K., Nakahara, Y., Enomoto, A., Hino, J., Ando, A., Inoue, M., Shiraki, Y., Omote, N., Kusaka, M., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0484oc · Cited by 18
High-Resolution Computed Tomography of Fibrotic Interstitial Lung Disease
Rodriguez, K. J., Ashby‐Padial, C., Rullán-Varela, V., & Sharma, A. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1755563 · Cited by 18
Chen, H., Luo, Y., Zhu, Y., Ye, Y., Chen, D., Song, X., Xiao, Z., Liu, M., & Li, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1070736 · Cited by 17
Niitsu, T., Fukushima, K., Komukai, S., Takata, S., Abe, Y., Nii, T., Kuge, T., Iwakoshi, S., Shiroyama, T., Miyake, K., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002667 · Cited by 16
Sgalla, G., Simonetti, J., Cortese, S., & Richeldi, L. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2173061 · Cited by 19
Shaikh, S. B., Goracci, C., Tjitropranoto, A., & Rahman, I. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2205127 · Cited by 16
An update on current and emerging drug treatments for idiopathic pulmonary fibrosis
Trachalaki, A., Sultana, N., & Wells, A. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2213436 · Cited by 15
Idiopathic pulmonary fibrosis: current diagnosis and treatment
Amaral, A. F., Colares, P. D. F. B., & Kairalla, R. A. (2023) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20230085 · Cited by 26
A role for the terminal C5-C9 complement pathway in idiopathic pulmonary fibrosis
Sikkeland, L. I. B., Ueland, T., Lund, M. B., Durheim, M. T., & Mollnes, T. E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1236495 · Cited by 19
Domvri, K., Organtzis, I., Apostolopoulos, A., Fouka, E., Kontakiotis, T., & Papakosta, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091307 · Cited by 16
Hadi, D. D., Marsool, M. D. M., Marsool, A. D. M., Vora, N., Al‐Badri, S. G., Al‐Fatlawi, N., Wssawi, A. F. A. A., Al‐Ibraheem, A. M. T., Hamza, K. A., Prajjwal, P., et al. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.1079 · Cited by 16
Selenite selectively kills lung fibroblasts to treat bleomycin-induced pulmonary fibrosis
Lin, J.-H., Liu, C., Liu, C., Hsu, T.-W., Yeh, Y., How, C., Hsu, H., & Hung, S. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103148 · Cited by 15
“Although two antifibrotic agents are available for IPF [3,4], their efficacy is limited and the cost is relatively high.”
BackgroundOrtíz, A. D. R., Jiménez-Rodríguez, B. M., Ramírez, C. L., López-Bauzá, Á., Perez-Morales, M. D., Delgado-Torralbo, J. A., Moral, C. V., & Navarrete, B. A. (2024) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2023-001687 · Cited by 26
Maddali, M. V., Moore, A. R., Sinha, P., Newton, C. A., Kim, J. S., Adegunsoye, A., Ma, S., Strek, M. E., Chen, C., Linderholm, A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0339oc · Cited by 17
Evidence from recent clinical trials in fibrotic interstitial lung diseases
Cottin, V., & Valenzuela, C. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001089 · Cited by 18
Open-Access Biorepository for Idiopathic Pulmonary Fibrosis. The Way Forward
White, E. S., Brown, K. M., Collard, H. R., Conoscenti, C., Cosgrove, G. P., Flaherty, K. R., Leff, J. A., Martínez, F. J., Roman, J., Rose, D., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201406-289oi · Cited by 15
Kulkarni, T., Willoughby, J., Lara, M. D. P. A., et al. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.04.010 · Cited by 15
Toll-like receptors and autophagy in interstitial lung diseases
Margaritopoulos, G. A., Lasithiotaki, I., & Antoniou, K. M. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.09.032 · Cited by 17
Clinical experience in idiopathic pulmonary fibrosis: a retrospective study
Guiot, J., Duysinx, B., Seidel, L., Henket, M. A., Gester, F., Bonhomme, O., Corhay, J.-L., & Louis, R. E. (2017) · Acta Clinica Belgica · doi:10.1080/17843286.2017.1399228 · Cited by 18
Kondoh, Y., Taniguchi, H., Kataoka, K., Furukawa, T., Shintani, A., Fujisawa, T., Suda, T., Arita, M., Baba, T., Ichikado, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193608 · Cited by 15
Therapeutic burden in interstitial lung disease: Lessons to learn
Khor, Y. H., Glaspole, I., & Goh, N. S. L. (2019) · Respirology · doi:10.1111/resp.13480 · Cited by 15
Self-citationKhan, F., Stewart, I. D., Howard, L., McKeever, T. M., Jones, S., Hearson, G., Braybrooke, R., Edwards, C. C., Jenkins, G. R., & Saini, G. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000439 · Cited by 17
Barnikel, M., Million, P. M., Knoop, H., & Behr, J. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.06.013 · Cited by 15
Objectively Measured Chronic Lung Injury on Chest CT
Harmouche, R., Ash, S. Y., Putman, R. K., Hunninghake, G. M., Estépar, R. S. J., Martínez, F. J., Choi, A. M. K., Lynch, D. A., Hatabu, H., Han, M. K., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.020 · Cited by 16
Raupp, D., Fernandes, R. S., Antunes, K. H., Perin, F. A., & Rigatto, K. (2020) · Peptides · doi:10.1016/j.peptides.2020.170384 · Cited by 15
“Currently, the two drugs (pirfenidone and nintedanib) used to treat the disease are expensive and promote only a small reduction in lung function decline [12,13].”
Sgalla, G., Larici, A. R., Golfi, N., Calvello, M., Farchione, A., del Ciello, A., Varone, F., Iovene, B., Manfredi, R. M., & Richeldi, L. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01289-2 · Cited by 19
“Despite two antifibrotic drugs, nintedanib and pirfenidone, proved to slow down the functional decline in IPF [4, 5], most patients still deteriorate despite treatment.”
BackgroundAmlani, B., Elsayed, G., Barvalia, U., et al. (2020) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v37i2.8461 · Cited by 15
Jin, D., An, X., Zhang, Y., Zhao, S., Duan, L., Duan, Y., Lian, F., & Tong, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.602218 · Cited by 19
Treatment of Idiopathic Pulmonary Fibrosis
Abuserewa, S. T. H., Duff, R., & Becker, G. (2021) · Cureus · doi:10.7759/cureus.15360 · Cited by 18
Matsuo, S., Okamoto, M., Ikeuchi, T., Zaizen, Y., Inomoto, A., Haraguchi, R., Mori, S., Sasaki, R., Nouno, T., Tanaka, T., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143153 · Cited by 18
Myeloperoxidase and associated lung disease: Review of the latest developments
Hu, H., & Keat, K. (2021) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.14213 · Cited by 15
Lung cancer and interstitial lung diseases: the lack of prognostic impact of lung cancer in IPF
Carobene, L., Spina, D., Disanto, M. G., Micheletto, C., Mazzei, M. A., Paladini, P., Ghiribelli, C., Bargagli, E., & Rottoli, P. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02833-6 · Cited by 15
Identification of targetable kinases in idiopathic pulmonary fibrosis
Higo, H., Ohashi, K., Tomida, S., Okawa, S., Yamamoto, H., Sugimoto, S., Senoo, S., Makimoto, G., Ninomiya, K., Nakasuka, T., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-01940-y · Cited by 20
Impact of Palliative Care in End-of-Life of Fibrotic Interstitial Lung Disease Patients
Chai, G. T., Neo, H. Y., Abisheganaden, J. A., & Hum, A. Y. M. (2022) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221083575 · Cited by 18
The Association between Exposures and Disease Characteristics in Familial Pulmonary Fibrosis
Copeland, C. R., Donnelly, E. F., Mehrad, M., Ding, G., Markin, C. R., Douglas, K., Wu, P., Cogan, J. D., Young, L. R., Bartholmai, B. J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202203-267oc · Cited by 15
Self-citationZhou, C., Yang, Y., Lin, X., Fang, N., Chen, L., Jiang, J., Deng, H., Deng, Y., Wan, M., Qiu, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.935779 · Cited by 19
“Although there is no effective treatment to reverse fibrosis, nintedanib and pirfenidone can help to retard its progression (41, 42).”
BackgroundChen, C., Tung, H.-Y., Tseng, Y., Huang, J., Shi, L.-S., & Ye, Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120950 · Cited by 18
Nasonov, E. L., Ananyeva, L. P., & Avdeev, S. N. (2022) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2022-1 · Cited by 17
New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?
Rogler, G. (2014) · Digestive Diseases · doi:10.1159/000367825 · Cited by 15
Management of Connective Tissue Disease–associated Interstitial Lung Disease
Chartrand, S., & Fischer, A. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.01.002 · Cited by 15
Novel Treatments for Idiopathic Pulmonary Fibrosis
Spagnolo, P. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.003 · Cited by 15
Yin, N. B., Lepp, A., Ji, Y., Mortensen, M., Hou, S., Qi, X.-M., Myers, C. R., & Chen, G. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779488 · Cited by 18
Capparelli, I., Fernandez, M., Otero, M. S., Steimberg, J., Brassesco, M., Campobasso, A., Palacios, S., Caro, F. M., Alberti, M. L., Rabinovich, R., et al. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2017.09.004 · Cited by 22
Kobayashi, K., Suzukawa, M., Watanabe, K., Arakawa, S., Igarashi, S., Asari, I., Hebisawa, A., Matsui, H., Nagai, H., Nagase, T., et al. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13390 · Cited by 19
Finazzi, T., Ronden, M., Spoelstra, F. O. B., Nossent, E. J., Nijman, S. F. M., Bahce, I., Dickhoff, C., & Senan, S. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1730002 · Cited by 15
Martínez, J. A. B., Ferreira, J. C., Tanni, S. É., Alves, L. R., Cabral, B. F., de Carvalho, C. R. R., Cezare, T. J., da Costa, C. H., Gazzana, M. B., Jezler, S. F. D. O., et al. (2020) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20190423 · Cited by 17
Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management
Pérez, E. R. F., Koelsch, T. L., Leone, P. M., Groshong, S. D., Lynch, D. A., & Brown, K. K. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1701250 · Cited by 17
An updated safety review of the drug treatments for idiopathic pulmonary fibrosis
Sgalla, G., Comes, A., & Richeldi, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1921143 · Cited by 18
Li, G., Zhang, Y., Jiang, H., Wu, X., Hao, Y., Su, Y., Zou, Y., Xian, W., Wang, F., & Du, Q. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41628 · Cited by 23
Impact of Pulmonary Rehabilitation on Survival in People With Interstitial Lung Disease
Dowman, L., Vainshelboim, B., & Holland, A. E. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.01.001 · Cited by 16
Feng, Y., Su, Q., Zhu, J., Cui, X., Guo, J., Yang, J., & Zhang, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114144 · Cited by 16
Li, R. M., Tan, D. B. A., Tedja, C., Cooper, W. A., Jo, H. E., Grainge, C., Glaspole, I., Goh, N. S. L., Ellis, S. J., Hopkins, P. M.-A., et al. (2025) · Respirology · doi:10.1111/resp.14894 · Cited by 14
Self-citationQiu, Y., & Ye, W. (2025) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_132_25 · Cited by 16
Fibroblasts as regulators of lung immunity, repair and fibrosis
Bell, P. T., & Belz, G. T. (2026) · Nature reviews. Immunology · doi:10.1038/s41577-026-01268-4 · Cited by 20
Under‐recognised co‐morbidities in idiopathic pulmonary fibrosis: A review
de Boer, K., & Lee, J. S. (2015) · Respirology · doi:10.1111/resp.12622 · Cited by 15
Extended Delivery of Pirfenidone with Novel, Soft Contact Lenses In Vitro and In Vivo
Wu, C., Or, P. W., Chong, J. I. T., et al. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2020.0058 · Cited by 14
Wang, H., Yang, R., Jin, J., Wang, Z., & Li, W. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259784 · Cited by 16
Ageing with Interstitial lung disease: preserving health and well being
Saketkoo, L. A., Obi, O. N., Patterson, K. C., & Russell, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000880 · Cited by 15
Fan, G., Liu, J., Wu, Z. S., Li, C., & Zhang, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049361 · Cited by 26
Plant miRNA osa-miR172d-5p suppressed lung fibrosis by targeting Tab1
Kumazoe, M., Ogawa, F., Hikida, A., Shimada, Y., Yoshitomi, R., Watanabe, R., Onda, H., Fujimura, Y., & Tachibana, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-29188-6 · Cited by 15
Islam, M. A., Kibria, M. K., Hossen, M. B., Reza, M. S., Tasmia, S. A., Tuly, K. F., Mosharof, M. P., Kabir, S. R., Kabir, M. H., & Mollah, M. N. H. (2023) · Scientific Reports · doi:10.1038/s41598-023-31276-6 · Cited by 16
Štefániková, M., Doubková, M., Ovesná, P., Šterclová, M., Lacina, L., Žůrková, M., Plačková, M., Bartoš, V., Janíčková, I., Bittenglová, R., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02450-3 · Cited by 19
Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition
Calaras, D., Mathioudakis, A. G., Lázár, Z., & Corlăteanu, A. (2023) · Biomedicines · doi:10.3390/biomedicines11061636 · Cited by 17
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.